C
Bio-Techne Corporation
TECH
$60.24
$1.773.02%
C
Hold
2/7/2025Upgraded
Bio-Techne Corporation (TECH) was upgraded to C- from D+ on 2/7/2025 due to a noticeable increase in the growth index and valuation index. Operating cash flow increased 32.02% from $63.89M to $84.35M, earnings per share increased from $0.21 to $0.22, and total revenue increased 2.62% from $289.46M to $297.03M.
Bio-Techne Corporation (TECH) was upgraded to C- from D+ on 2/7/2025 due to a noticeable increase in the growth index and valuation index. Operating cash flow increased 32.02% from $63.89M to $84.35M, earnings per share increased from $0.21 to $0.22, and total revenue increased 2.62% from $289.46M to $297.03M.
D
Sell
2/3/2025Downgrade
Bio-Techne Corporation (TECH) was downgraded to D+ from C- on 2/3/2025 due to a decline in the growth index, valuation index and efficiency index. EBIT declined 23.55% from $68.7M to $52.52M, earnings per share declined from $0.257 to $0.21, and net income declined 17.22% from $40.59M to $33.6M.
Bio-Techne Corporation (TECH) was downgraded to D+ from C- on 2/3/2025 due to a decline in the growth index, valuation index and efficiency index. EBIT declined 23.55% from $68.7M to $52.52M, earnings per share declined from $0.257 to $0.21, and net income declined 17.22% from $40.59M to $33.6M.
C
Hold
10/28/2024Upgraded
Bio-Techne Corporation (TECH) was upgraded to C- from D+ on 10/28/2024 due to an increase in the total return index and valuation index.
Bio-Techne Corporation (TECH) was upgraded to C- from D+ on 10/28/2024 due to an increase in the total return index and valuation index.
D
Sell
9/20/2024Downgrade
Bio-Techne Corporation (TECH) was downgraded to D+ from C- on 9/20/2024 due to a major decline in the valuation index, total return index and efficiency index. Net income declined 17.27% from $49.06M to $40.59M, and total capital declined 0.83% from $2.51B to $2.49B.
Bio-Techne Corporation (TECH) was downgraded to D+ from C- on 9/20/2024 due to a major decline in the valuation index, total return index and efficiency index. Net income declined 17.27% from $49.06M to $40.59M, and total capital declined 0.83% from $2.51B to $2.49B.
C
Hold
11/8/2023Downgrade
Bio-Techne Corporation (TECH) was downgraded to C- from C on 11/8/2023 due to a significant decline in the growth index, volatility index and total return index. EBIT declined 33.45% from $83.46M to $55.54M, earnings per share declined from $0.4605 to $0.31, and operating cash flow declined 28.79% from $83.39M to $59.38M.
Bio-Techne Corporation (TECH) was downgraded to C- from C on 11/8/2023 due to a significant decline in the growth index, volatility index and total return index. EBIT declined 33.45% from $83.46M to $55.54M, earnings per share declined from $0.4605 to $0.31, and operating cash flow declined 28.79% from $83.39M to $59.38M.
C
Hold
2/16/2023Downgrade
Bio-Techne Corporation (TECH) was downgraded to C from C+ on 2/16/2023 due to a noticeable decline in the growth index, total return index and volatility index. Earnings per share declined from $0.5525 to $0.31.
Bio-Techne Corporation (TECH) was downgraded to C from C+ on 2/16/2023 due to a noticeable decline in the growth index, total return index and volatility index. Earnings per share declined from $0.5525 to $0.31.
C
Hold
7/8/2022Upgraded
Bio-Techne Corporation (TECH) was upgraded to C+ from C on 7/8/2022 due to an increase in the total return index and valuation index.
Bio-Techne Corporation (TECH) was upgraded to C+ from C on 7/8/2022 due to an increase in the total return index and valuation index.
C
Hold
6/13/2022Downgrade
Bio-Techne Corporation (TECH) was downgraded to C from C+ on 6/13/2022 due to a significant decline in the total return index, volatility index and solvency index. The quick ratio declined from 2.79 to 2.6.
Bio-Techne Corporation (TECH) was downgraded to C from C+ on 6/13/2022 due to a significant decline in the total return index, volatility index and solvency index. The quick ratio declined from 2.79 to 2.6.
C
Hold
11/29/2021Downgrade
Bio-Techne Corporation (TECH) was downgraded to C+ from B on 11/29/2021 due to a substantial decline in the total return index.
Bio-Techne Corporation (TECH) was downgraded to C+ from B on 11/29/2021 due to a substantial decline in the total return index.
B
Buy
11/24/2021Upgraded
Bio-Techne Corporation (TECH) was upgraded to B from B- on 11/24/2021 due to an increase in the total return index, volatility index and valuation index.
Bio-Techne Corporation (TECH) was upgraded to B from B- on 11/24/2021 due to an increase in the total return index, volatility index and valuation index.
B
Buy
11/10/2021Upgraded
Bio-Techne Corporation (TECH) was upgraded to B- from C+ on 11/10/2021 due to a significant increase in the growth index, volatility index and valuation index. Earnings per share increased from $0.3694 to $1.69.
Bio-Techne Corporation (TECH) was upgraded to B- from C+ on 11/10/2021 due to a significant increase in the growth index, volatility index and valuation index. Earnings per share increased from $0.3694 to $1.69.
C
Hold
9/16/2021Upgraded
Bio-Techne Corporation (TECH) was upgraded to C+ from C on 9/16/2021 due to a noticeable increase in the total return index and volatility index.
Bio-Techne Corporation (TECH) was upgraded to C+ from C on 9/16/2021 due to a noticeable increase in the total return index and volatility index.
C
Hold
9/1/2021Downgrade
Bio-Techne Corporation (TECH) was downgraded to C from C+ on 9/1/2021 due to a decline in the total return index and valuation index.
Bio-Techne Corporation (TECH) was downgraded to C from C+ on 9/1/2021 due to a decline in the total return index and valuation index.
C
Hold
8/27/2021Downgrade
Bio-Techne Corporation (TECH) was downgraded to C+ from B- on 8/27/2021 due to a significant decline in the growth index, valuation index and efficiency index. Net income declined 67.32% from $45.78M to $14.96M, and earnings per share declined from $1.12 to $0.3694.
Bio-Techne Corporation (TECH) was downgraded to C+ from B- on 8/27/2021 due to a significant decline in the growth index, valuation index and efficiency index. Net income declined 67.32% from $45.78M to $14.96M, and earnings per share declined from $1.12 to $0.3694.
B
Buy
8/17/2021Downgrade
Bio-Techne Corporation (TECH) was downgraded to B- from B on 8/17/2021 due to a large decline in the total return index.
Bio-Techne Corporation (TECH) was downgraded to B- from B on 8/17/2021 due to a large decline in the total return index.
B
Buy
8/2/2021Upgraded
Bio-Techne Corporation (TECH) was upgraded to B from C+ on 8/2/2021 due to a substantial increase in the total return index.
Bio-Techne Corporation (TECH) was upgraded to B from C+ on 8/2/2021 due to a substantial increase in the total return index.
C
Hold
7/20/2021Downgrade
Bio-Techne Corporation (TECH) was downgraded to C+ from B- on 7/20/2021 due to a decline in the total return index and valuation index.
Bio-Techne Corporation (TECH) was downgraded to C+ from B- on 7/20/2021 due to a decline in the total return index and valuation index.
B
Buy
7/1/2021Upgraded
Bio-Techne Corporation (TECH) was upgraded to B- from C+ on 7/1/2021 due to an increase in the total return index.
Bio-Techne Corporation (TECH) was upgraded to B- from C+ on 7/1/2021 due to an increase in the total return index.
C
Hold
6/15/2021Downgrade
Bio-Techne Corporation (TECH) was downgraded to C+ from B- on 6/15/2021 due to a large decline in the total return index and valuation index.
Bio-Techne Corporation (TECH) was downgraded to C+ from B- on 6/15/2021 due to a large decline in the total return index and valuation index.
B
Buy
5/26/2021Upgraded
Bio-Techne Corporation (TECH) was upgraded to B- from C+ on 5/26/2021 due to a noticeable increase in the total return index and valuation index.
Bio-Techne Corporation (TECH) was upgraded to B- from C+ on 5/26/2021 due to a noticeable increase in the total return index and valuation index.
C
Hold
5/11/2021Downgrade
Bio-Techne Corporation (TECH) was downgraded to C+ from B- on 5/11/2021 due to a noticeable decline in the growth index and volatility index. Operating cash flow declined 16.13% from $89.27M to $74.87M, and earnings per share declined from $1.15 to $1.12.
Bio-Techne Corporation (TECH) was downgraded to C+ from B- on 5/11/2021 due to a noticeable decline in the growth index and volatility index. Operating cash flow declined 16.13% from $89.27M to $74.87M, and earnings per share declined from $1.15 to $1.12.
B
Buy
4/26/2021Downgrade
Bio-Techne Corporation (TECH) was downgraded to B- from B on 4/26/2021 due to a large decline in the total return index, volatility index and valuation index.
Bio-Techne Corporation (TECH) was downgraded to B- from B on 4/26/2021 due to a large decline in the total return index, volatility index and valuation index.
B
Buy
4/7/2021Upgraded
Bio-Techne Corporation (TECH) was upgraded to B from B- on 4/7/2021 due to a large increase in the total return index and volatility index.
Bio-Techne Corporation (TECH) was upgraded to B from B- on 4/7/2021 due to a large increase in the total return index and volatility index.
B
Buy
3/18/2021Downgrade
Bio-Techne Corporation (TECH) was downgraded to B- from B on 3/18/2021 due to a large decline in the total return index.
Bio-Techne Corporation (TECH) was downgraded to B- from B on 3/18/2021 due to a large decline in the total return index.
B
Buy
3/2/2021Upgraded
Bio-Techne Corporation (TECH) was upgraded to B from B- on 3/2/2021 due to a large increase in the total return index, volatility index and valuation index.
Bio-Techne Corporation (TECH) was upgraded to B from B- on 3/2/2021 due to a large increase in the total return index, volatility index and valuation index.
B
Buy
2/25/2021Upgraded
Bio-Techne Corporation (TECH) was upgraded to B- from C+ on 2/25/2021 due to an increase in the volatility index and total return index.
Bio-Techne Corporation (TECH) was upgraded to B- from C+ on 2/25/2021 due to an increase in the volatility index and total return index.
C
Hold
2/10/2021Downgrade
Bio-Techne Corporation (TECH) was downgraded to C+ from B- on 2/10/2021 due to a large decline in the valuation index and efficiency index. Total capital declined 0.91% from $1.85B to $1.84B.
Bio-Techne Corporation (TECH) was downgraded to C+ from B- on 2/10/2021 due to a large decline in the valuation index and efficiency index. Total capital declined 0.91% from $1.85B to $1.84B.
B
Buy
1/27/2021Downgrade
Bio-Techne Corporation (TECH) was downgraded to B- from B on 1/27/2021 due to a large decline in the total return index, valuation index and volatility index.
Bio-Techne Corporation (TECH) was downgraded to B- from B on 1/27/2021 due to a large decline in the total return index, valuation index and volatility index.
B
Buy
1/11/2021Upgraded
Bio-Techne Corporation (TECH) was upgraded to B from B- on 1/11/2021 due to a substantial increase in the total return index and volatility index.
Bio-Techne Corporation (TECH) was upgraded to B from B- on 1/11/2021 due to a substantial increase in the total return index and volatility index.
B
Buy
11/16/2020Upgraded
Bio-Techne Corporation (TECH) was upgraded to B- from C+ on 11/16/2020 due to a significant increase in the growth index, volatility index and efficiency index. EBIT increased 50.38% from $32.55M to $48.94M, operating cash flow increased 47.37% from $44.79M to $66.01M, and total revenue increased 16.13% from $175.83M to $204.2M.
Bio-Techne Corporation (TECH) was upgraded to B- from C+ on 11/16/2020 due to a significant increase in the growth index, volatility index and efficiency index. EBIT increased 50.38% from $32.55M to $48.94M, operating cash flow increased 47.37% from $44.79M to $66.01M, and total revenue increased 16.13% from $175.83M to $204.2M.
C
Hold
10/19/2020Downgrade
Bio-Techne Corporation (TECH) was downgraded to C+ from B- on 10/19/2020 due to a noticeable decline in the total return index and valuation index.
Bio-Techne Corporation (TECH) was downgraded to C+ from B- on 10/19/2020 due to a noticeable decline in the total return index and valuation index.
B
Buy
10/2/2020Upgraded
Bio-Techne Corporation (TECH) was upgraded to B- from C+ on 10/2/2020 due to a large increase in the total return index, valuation index and volatility index.
Bio-Techne Corporation (TECH) was upgraded to B- from C+ on 10/2/2020 due to a large increase in the total return index, valuation index and volatility index.
C
Hold
9/16/2020Downgrade
Bio-Techne Corporation (TECH) was downgraded to C+ from B- on 9/16/2020 due to a substantial decline in the total return index.
Bio-Techne Corporation (TECH) was downgraded to C+ from B- on 9/16/2020 due to a substantial decline in the total return index.
B
Buy
8/28/2020Downgrade
Bio-Techne Corporation (TECH) was downgraded to B- from B on 8/28/2020 due to a significant decline in the growth index and volatility index. EBIT declined 31.44% from $47.47M to $32.55M, total revenue declined 9.68% from $194.68M to $175.83M, and operating cash flow declined 9.46% from $49.47M to $44.79M.
Bio-Techne Corporation (TECH) was downgraded to B- from B on 8/28/2020 due to a significant decline in the growth index and volatility index. EBIT declined 31.44% from $47.47M to $32.55M, total revenue declined 9.68% from $194.68M to $175.83M, and operating cash flow declined 9.46% from $49.47M to $44.79M.
B
Buy
6/10/2020Upgraded
Bio-Techne Corporation (TECH) was upgraded to B from B- on 6/10/2020 due to a substantial increase in the total return index and efficiency index. Total capital increased 0.57% from $1.8B to $1.81B.
Bio-Techne Corporation (TECH) was upgraded to B from B- on 6/10/2020 due to a substantial increase in the total return index and efficiency index. Total capital increased 0.57% from $1.8B to $1.81B.
B
Buy
4/2/2020Downgrade
Bio-Techne Corporation (TECH) was downgraded to B- from B on 4/2/2020 due to a noticeable decline in the total return index and volatility index.
Bio-Techne Corporation (TECH) was downgraded to B- from B on 4/2/2020 due to a noticeable decline in the total return index and volatility index.
B
Buy
2/7/2020Upgraded
Bio-Techne Corporation (TECH) was upgraded to B from C on 2/7/2020 due to a significant increase in the growth index, valuation index and total return index. Earnings per share increased from $0.37 to $3.02, operating cash flow increased 73.7% from $40.54M to $70.42M, and EBIT increased 2.19% from $35.34M to $36.11M.
Bio-Techne Corporation (TECH) was upgraded to B from C on 2/7/2020 due to a significant increase in the growth index, valuation index and total return index. Earnings per share increased from $0.37 to $3.02, operating cash flow increased 73.7% from $40.54M to $70.42M, and EBIT increased 2.19% from $35.34M to $36.11M.
C
Hold
8/30/2019Downgrade
Bio-Techne Corporation (TECH) was downgraded to C from C+ on 8/30/2019 due to a significant decline in the growth index, valuation index and total return index. Earnings per share declined from $1.15 to $0.4215, and EBIT declined 2.5% from $44.63M to $43.51M.
Bio-Techne Corporation (TECH) was downgraded to C from C+ on 8/30/2019 due to a significant decline in the growth index, valuation index and total return index. Earnings per share declined from $1.15 to $0.4215, and EBIT declined 2.5% from $44.63M to $43.51M.
C
Hold
8/13/2019Downgrade
Bio-Techne Corporation (TECH) was downgraded to C+ from B- on 8/13/2019 due to a major decline in the total return index and volatility index.
Bio-Techne Corporation (TECH) was downgraded to C+ from B- on 8/13/2019 due to a major decline in the total return index and volatility index.
B
Buy
5/9/2019Upgraded
Bio-Techne Corporation (TECH) was upgraded to B- from C+ on 5/9/2019 due to a significant increase in the growth index, valuation index and solvency index. Earnings per share increased from $0.45 to $1.15, EBIT increased 27.92% from $34.89M to $44.63M, and debt to equity declined from 0.5 to 0.46.
Bio-Techne Corporation (TECH) was upgraded to B- from C+ on 5/9/2019 due to a significant increase in the growth index, valuation index and solvency index. Earnings per share increased from $0.45 to $1.15, EBIT increased 27.92% from $34.89M to $44.63M, and debt to equity declined from 0.5 to 0.46.
C
Hold
4/3/2019Upgraded
Bio-Techne Corporation (TECH) was upgraded to C+ from C on 4/3/2019 due to a significant increase in the total return index and volatility index.
Bio-Techne Corporation (TECH) was upgraded to C+ from C on 4/3/2019 due to a significant increase in the total return index and volatility index.
C
Hold
2/11/2019Downgrade
Bio-Techne Corporation (TECH) was downgraded to C from C+ on 2/11/2019 due to a major decline in the valuation index, growth index and efficiency index. Total capital declined 1.44% from $1.67B to $1.65B.
Bio-Techne Corporation (TECH) was downgraded to C from C+ on 2/11/2019 due to a major decline in the valuation index, growth index and efficiency index. Total capital declined 1.44% from $1.67B to $1.65B.
C
Hold
1/22/2019Downgrade
Bio-Techne Corporation (TECH) was downgraded to C+ from B- on 1/22/2019 due to a noticeable decline in the volatility index, total return index and valuation index.
Bio-Techne Corporation (TECH) was downgraded to C+ from B- on 1/22/2019 due to a noticeable decline in the volatility index, total return index and valuation index.
B
Buy
12/19/2018Downgrade
Bio-Techne Corporation (TECH) was downgraded to B- from B on 12/19/2018 due to a major decline in the total return index, growth index and efficiency index. Earnings per share declined from $1.0888 to $0.45, net income declined 58.27% from $41.7M to $17.4M, and operating cash flow declined 39.16% from $64.84M to $39.45M.
Bio-Techne Corporation (TECH) was downgraded to B- from B on 12/19/2018 due to a major decline in the total return index, growth index and efficiency index. Earnings per share declined from $1.0888 to $0.45, net income declined 58.27% from $41.7M to $17.4M, and operating cash flow declined 39.16% from $64.84M to $39.45M.
B
Buy
5/16/2018Upgraded
Bio-Techne Corporation (TECH) was upgraded to B from B- on 5/16/2018 due to an increase in the volatility index, solvency index and valuation index. The quick ratio increased from 2.34 to 4.04.
Bio-Techne Corporation (TECH) was upgraded to B from B- on 5/16/2018 due to an increase in the volatility index, solvency index and valuation index. The quick ratio increased from 2.34 to 4.04.
B
Buy
5/1/2018Downgrade
Bio-Techne Corporation (TECH) was downgraded to B- from B on 5/1/2018 due to a decline in the volatility index, valuation index and dividend index.
Bio-Techne Corporation (TECH) was downgraded to B- from B on 5/1/2018 due to a decline in the volatility index, valuation index and dividend index.
B
Buy
2/9/2018Upgraded
Bio-Techne Corporation (TECH) was upgraded to B from C on 2/9/2018 due to a significant increase in the growth index, valuation index and total return index. Earnings per share increased from $0.42 to $1.29, total revenue increased 6.6% from $144.61M to $154.15M, and EBIT increased 4.67% from $35.97M to $37.65M.
Bio-Techne Corporation (TECH) was upgraded to B from C on 2/9/2018 due to a significant increase in the growth index, valuation index and total return index. Earnings per share increased from $0.42 to $1.29, total revenue increased 6.6% from $144.61M to $154.15M, and EBIT increased 4.67% from $35.97M to $37.65M.
C
Hold
11/13/2017Downgrade
Bio-Techne Corporation (TECH) was downgraded to C from C+ on 11/13/2017 due to a major decline in the growth index, efficiency index and valuation index. Earnings per share declined from $0.8594 to $0.42, net income declined 50.59% from $32.1M to $15.86M, and operating cash flow declined 12.06% from $50.83M to $44.7M.
Bio-Techne Corporation (TECH) was downgraded to C from C+ on 11/13/2017 due to a major decline in the growth index, efficiency index and valuation index. Earnings per share declined from $0.8594 to $0.42, net income declined 50.59% from $32.1M to $15.86M, and operating cash flow declined 12.06% from $50.83M to $44.7M.
C
Hold
9/8/2017Upgraded
Bio-Techne Corporation (TECH) was upgraded to C+ from C on 9/8/2017 due to a noticeable increase in the growth index, volatility index and total return index. Operating cash flow increased 103.81% from $24.94M to $50.83M, earnings per share increased from $0.57 to $0.8594, and total revenue increased 8.71% from $144.04M to $156.58M.
Bio-Techne Corporation (TECH) was upgraded to C+ from C on 9/8/2017 due to a noticeable increase in the growth index, volatility index and total return index. Operating cash flow increased 103.81% from $24.94M to $50.83M, earnings per share increased from $0.57 to $0.8594, and total revenue increased 8.71% from $144.04M to $156.58M.
C
Hold
1/9/2017Downgrade
Bio-Techne Corporation (TECH) was downgraded to C from C+ on 1/9/2017 due to a noticeable decline in the volatility index, solvency index and valuation index.
Bio-Techne Corporation (TECH) was downgraded to C from C+ on 1/9/2017 due to a noticeable decline in the volatility index, solvency index and valuation index.
C
Hold
11/11/2016Downgrade
Bio-Techne Corp. (TECH) was downgraded to C+ from B- on 11/11/2016 due to a decline in the growth index, efficiency index and valuation index. Earnings per share declined from $0.6884 to $0.43, net income declined 36.47% from $25.63M to $16.28M, and operating cash flow declined 28.35% from $36.36M to $26.05M.
Bio-Techne Corp. (TECH) was downgraded to C+ from B- on 11/11/2016 due to a decline in the growth index, efficiency index and valuation index. Earnings per share declined from $0.6884 to $0.43, net income declined 36.47% from $25.63M to $16.28M, and operating cash flow declined 28.35% from $36.36M to $26.05M.
B
Buy
11/3/2016Upgraded
Bio-Techne Corp. (TECH) was upgraded to B- from C+ on 11/3/2016 due to an increase in the valuation index, volatility index and dividend index.
Bio-Techne Corp. (TECH) was upgraded to B- from C+ on 11/3/2016 due to an increase in the valuation index, volatility index and dividend index.
C
Hold
10/19/2016Downgrade
Bio-Techne Corp. (TECH) was downgraded to C+ from B- on 10/19/2016 due to a major decline in the total return index, valuation index and dividend index.
Bio-Techne Corp. (TECH) was downgraded to C+ from B- on 10/19/2016 due to a major decline in the total return index, valuation index and dividend index.
B
Buy
8/31/2016Downgrade
Bio-Techne Corp. (TECH) was downgraded to B- from B on 8/31/2016 due to a major decline in the growth index. Earnings per share declined from $0.81 to $0.6884, EBIT declined 13.51% from $45.92M to $39.72M, and operating cash flow declined 2.09% from $37.14M to $36.36M.
Bio-Techne Corp. (TECH) was downgraded to B- from B on 8/31/2016 due to a major decline in the growth index. Earnings per share declined from $0.81 to $0.6884, EBIT declined 13.51% from $45.92M to $39.72M, and operating cash flow declined 2.09% from $37.14M to $36.36M.
B
Buy
6/24/2016Upgraded
Bio-Techne Corp. (TECH) was upgraded to B from B- on 6/24/2016 due to a major increase in the total return index and volatility index.
Bio-Techne Corp. (TECH) was upgraded to B from B- on 6/24/2016 due to a major increase in the total return index and volatility index.
B
Buy
5/12/2016Upgraded
Bio-Techne Corp. (TECH) was upgraded to B- from C+ on 5/12/2016 due to an increase in the growth index, total return index and valuation index. EBIT increased 21.04% from $37.94M to $45.92M, earnings per share increased from $0.69 to $0.81, and total revenue increased 8.33% from $120.91M to $130.97M.
Bio-Techne Corp. (TECH) was upgraded to B- from C+ on 5/12/2016 due to an increase in the growth index, total return index and valuation index. EBIT increased 21.04% from $37.94M to $45.92M, earnings per share increased from $0.69 to $0.81, and total revenue increased 8.33% from $120.91M to $130.97M.
C
Hold
3/16/2016Downgrade
Bio-Techne Corp. (TECH) was downgraded to C+ from B- on 3/16/2016 due to a decline in the valuation index, total return index and dividend index.
Bio-Techne Corp. (TECH) was downgraded to C+ from B- on 3/16/2016 due to a decline in the valuation index, total return index and dividend index.
B
Buy
3/1/2016Upgraded
Bio-Techne Corp. (TECH) was upgraded to B- from C+ on 3/1/2016 due to a large increase in the growth index and solvency index. The quick ratio increased from 3.53 to 5.06, operating cash flow increased 21.07% from $31.83M to $38.54M, and EBIT increased 16.95% from $32.44M to $37.94M.
Bio-Techne Corp. (TECH) was upgraded to B- from C+ on 3/1/2016 due to a large increase in the growth index and solvency index. The quick ratio increased from 3.53 to 5.06, operating cash flow increased 21.07% from $31.83M to $38.54M, and EBIT increased 16.95% from $32.44M to $37.94M.
C
Hold
1/4/2016Downgrade
Bio-Techne Corp. (TECH) was downgraded to C+ from B- on 1/4/2016 due to a decline in the total return index, volatility index and valuation index.
Bio-Techne Corp. (TECH) was downgraded to C+ from B- on 1/4/2016 due to a decline in the total return index, volatility index and valuation index.
B
Buy
11/12/2015Downgrade
Bio-Techne Corp. (TECH) was downgraded to B- from B on 11/12/2015 due to a noticeable decline in the volatility index, total return index and growth index. EBIT declined 19.14% from $40.12M to $32.44M, operating cash flow declined 14.29% from $37.14M to $31.83M, and earnings per share declined from $0.7 to $0.61.
Bio-Techne Corp. (TECH) was downgraded to B- from B on 11/12/2015 due to a noticeable decline in the volatility index, total return index and growth index. EBIT declined 19.14% from $40.12M to $32.44M, operating cash flow declined 14.29% from $37.14M to $31.83M, and earnings per share declined from $0.7 to $0.61.
B
Buy
7/16/2015Upgraded
Bio-Techne Corp. (TECH) was upgraded to B from B- on 7/16/2015 due to an increase in the volatility index.
Bio-Techne Corp. (TECH) was upgraded to B from B- on 7/16/2015 due to an increase in the volatility index.
B
Buy
6/15/2015Downgrade
Bio-Techne Corp. (TECH) was downgraded to B- from B on 6/15/2015 due to a substantial decline in the growth index, volatility index and valuation index. Earnings per share declined from $0.89 to $0.65, and operating cash flow declined 13.86% from $35.73M to $30.78M.
Bio-Techne Corp. (TECH) was downgraded to B- from B on 6/15/2015 due to a substantial decline in the growth index, volatility index and valuation index. Earnings per share declined from $0.89 to $0.65, and operating cash flow declined 13.86% from $35.73M to $30.78M.
B
Buy
3/2/2015Downgrade
Bio-Techne Corp. (TECH) was downgraded to B from B+ on 3/2/2015 due to a decline in the valuation index and dividend index.
Bio-Techne Corp. (TECH) was downgraded to B from B+ on 3/2/2015 due to a decline in the valuation index and dividend index.
B
Buy
2/13/2015Upgraded
Bio-Techne Corp. (TECH) was upgraded to B+ from B on 2/13/2015 due to a noticeable increase in the growth index, volatility index and efficiency index. Earnings per share increased from $0.64 to $0.89, net income increased 38.91% from $23.91M to $33.21M, and total capital increased 6.46% from $918.36M to $977.7M.
Bio-Techne Corp. (TECH) was upgraded to B+ from B on 2/13/2015 due to a noticeable increase in the growth index, volatility index and efficiency index. Earnings per share increased from $0.64 to $0.89, net income increased 38.91% from $23.91M to $33.21M, and total capital increased 6.46% from $918.36M to $977.7M.
B
Buy
4/23/2014Downgrade
Techne Corp. (TECH) was downgraded to B from B+ on 4/23/2014 due to a noticeable decline in the volatility index.
Techne Corp. (TECH) was downgraded to B from B+ on 4/23/2014 due to a noticeable decline in the volatility index.
B
Buy
4/8/2014Upgraded
Techne Corp. (TECH) was upgraded to B+ from B on 4/8/2014 due to an increase in the valuation index, growth index and efficiency index.
Techne Corp. (TECH) was upgraded to B+ from B on 4/8/2014 due to an increase in the valuation index, growth index and efficiency index.
NASDAQ
03/12/2025 4:00PM Eastern
Quotes delayed
